KemPharm (NASDAQ:KMPH) has been assigned a $9.00 price objective by equities research analysts at Royal Bank of Canada in a report released on Tuesday. The firm currently has a “buy” rating on the specialty pharmaceutical company’s stock. Royal Bank of Canada’s price objective would indicate a potential upside of 81.82% from the stock’s previous close.
Other research analysts have also recently issued research reports about the company. Zacks Investment Research upgraded KemPharm from a “hold” rating to a “buy” rating and set a $4.25 price target on the stock in a research report on Wednesday, November 15th. ValuEngine raised KemPharm from a “strong sell” rating to a “sell” rating in a research note on Sunday, December 31st. One investment analyst has rated the stock with a sell rating, one has given a hold rating and four have issued a buy rating to the stock. The company currently has a consensus rating of “Buy” and a consensus target price of $8.35.
Shares of KemPharm (NASDAQ KMPH) traded down $0.05 during midday trading on Tuesday, hitting $4.95. The company had a trading volume of 61,800 shares, compared to its average volume of 83,510. The company has a quick ratio of 7.56, a current ratio of 7.56 and a debt-to-equity ratio of -1.92. KemPharm has a 52 week low of $2.45 and a 52 week high of $5.40. The company has a market capitalization of $71.75 and a PE ratio of -1.70.
In other KemPharm news, EVP Daniel L. Cohen acquired 7,500 shares of KemPharm stock in a transaction that occurred on Monday, November 27th. The shares were acquired at an average cost of $3.79 per share, with a total value of $28,425.00. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Company insiders own 25.40% of the company’s stock.
An institutional investor recently raised its position in KemPharm stock. Alyeska Investment Group L.P. grew its position in shares of KemPharm, Inc. (NASDAQ:KMPH) by 1.8% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 992,338 shares of the specialty pharmaceutical company’s stock after purchasing an additional 17,721 shares during the quarter. Alyeska Investment Group L.P. owned approximately 6.77% of KemPharm worth $3,672,000 as of its most recent SEC filing. Hedge funds and other institutional investors own 36.04% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: “KemPharm (KMPH) Given a $9.00 Price Target by Royal Bank of Canada Analysts” was originally posted by Ticker Report and is the property of of Ticker Report. If you are accessing this news story on another publication, it was illegally stolen and republished in violation of United States and international copyright and trademark laws. The correct version of this news story can be viewed at https://www.tickerreport.com/banking-finance/3142752/kempharm-kmph-given-a-9-00-price-target-by-royal-bank-of-canada-analysts.html.
KemPharm Company Profile
KemPharm, Inc is a clinical-stage specialty pharmaceutical company. The Company is engaged in the discovery and development of prodrugs. The Company uses its Ligand Activated Therapy (LAT) platform technology to create prodrugs. The Company’s product candidate, KP201/APAP, consists of KP201, its prodrug of hydrocodone, which is combined with acetaminophen (APAP).
Receive News & Ratings for KemPharm Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for KemPharm and related companies with MarketBeat.com's FREE daily email newsletter.